miR-155 targets SOCS1 to strengthen inflammation mediated by Th17 in AP, while miR-155 inhibition vigorously impedes inflammation and ameliorates pancreatic pathology [29]. Here, SOCS1 is linked to alkaline phosphatase measurement.